Quarterly report · Q3
4671.TEDINET S100Q645
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥35.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥50.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥36.4bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥2.5bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥3.8bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥2.7bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.1bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥2.7bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥4.0bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.5bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.5bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.5bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥2.5bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥38.3bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥40.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥38.7bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥13.6bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥16.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥24.7bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥23.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥22.4bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.0bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥146.88 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.43 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥339 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥242.32 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.08 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥146.23 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥336.99 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥241.23 | 2021-04-01 → 2021-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 64.2% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.6% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥6m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥362m |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥23.9bn |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥23.9bn |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥5m |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.3bn |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥12.0bn |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥12.0bn |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥0 |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥590m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥35.9bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥35.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6m |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥2.9bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥12m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥12m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥279m |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥24.2bn |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥24.2bn |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥11m |
| jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥3.3bn |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥12.3bn |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥12.3bn |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥0 |
| jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥770m |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥36.5bn |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥36.4bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥12m |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | ¥4.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 355
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |